Impact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.

ABSTRACT:

Background

Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy.

Objective

Investigation of outcomes for concomitant BTT in a post hoc analysis of the COU-AA-302 trial, which demonstrated an overall clinical benefit of abiraterone acetate (AA) plus prednisone over placebo plus prednisone in asymptomatic or mildly symptomatic chemotherapy-naïve mCRPC patients.

Design, setting, and participants

This report describes the third interim analysis (prespecified at 55% overall survival [OS] events) for the COU-AA-302 trial.

Intervention

Patients were grouped by concomitant BTT use or no BTT use.

Outcome measurements and statistical analysis

Radiographic prog

SUBMITTER: Saad F 

PROVIDER: S-EPMC5056561 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature